Vorinostat

Vorinostat

File:Vorinostat.svg
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Vorinostat
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Oral
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	71%
Metabolism	Hepatic glucuronidation and oxidation CYP system not involved
Elimination half-life	2 hours
Excretion	Renal (negligible)
Identifiers
IUPAC name N-hydroxy-N'-phenyl-octanediamide
CAS Number	149647-78-9
PubChem CID	5311
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H20N2O3
Molar mass	264.32 g/mol

WikiDoc Resources for Vorinostat
Articles
Most recent articles on Vorinostat Most cited articles on Vorinostat Review articles on Vorinostat Articles on Vorinostat in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Vorinostat Images of Vorinostat Photos of Vorinostat Podcasts & MP3s on Vorinostat Videos on Vorinostat
Evidence Based Medicine
Cochrane Collaboration on Vorinostat Bandolier on Vorinostat TRIP on Vorinostat
Clinical Trials
Ongoing Trials on Vorinostat at Clinical Trials.gov Trial results on Vorinostat Clinical Trials on Vorinostat at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Vorinostat NICE Guidance on Vorinostat NHS PRODIGY Guidance FDA on Vorinostat CDC on Vorinostat
Books
Books on Vorinostat
News
Vorinostat in the news Be alerted to news on Vorinostat News trends on Vorinostat
Commentary
Blogs on Vorinostat
Definitions
Definitions of Vorinostat
Patient Resources / Community
Patient resources on Vorinostat Discussion groups on Vorinostat Patient Handouts on Vorinostat Directions to Hospitals Treating Vorinostat Risk calculators and risk factors for Vorinostat
Healthcare Provider Resources
Symptoms of Vorinostat Causes & Risk Factors for Vorinostat Diagnostic studies for Vorinostat Treatment of Vorinostat
Continuing Medical Education (CME)
CME Programs on Vorinostat
International
Vorinostat en Espanol Vorinostat en Francais
Business
Vorinostat in the Marketplace Patents on Vorinostat
Experimental / Informatics
List of terms related to Vorinostat

Overview

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), brand name Zolinza®, is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors.

A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.

Zolinza was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006, and it is manufactured by Pantheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., White House Station, New Jersey.

References

• "ZOLINZA™, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration" (Press release). Merck & Co. June 7, 2006. Retrieved 2006-10-06.

• "FDA Approves New Drug for Skin Cancer, Zolinza" (Press release). Food and Drug Administration. October 6, 2006. Retrieved 2006-10-06.

• "Vorinostat shows anti-cancer activity in recurrent gliomas" (Press release). Mayo Clinic. June 3, 2007. Retrieved 2007-06-03.